Skip to main content
Premium Trial:

Request an Annual Quote

Astute Medical Raises $6.2M in Series A Round

NEW YORK (GenomeWeb News) – Astute Medical said today that it has raised $6.2 million in a Series A round of financing led by De Novo Ventures.
 
San Diego-based Astute is developing protein biomarker-based tests for the rapid diagnosis and risk assessment of patients with hospital-acquired infections. The firm said it would use the funds from the first round of financing for research and development of the biomarkers.
 
Astute was founded last year and is led by CEO Christopher Hibberd, a former SVP of corporate development at Biosite, and CSO Paul McPherson, a former VP of research and development at Biosite, which was acquired last year for $1.7 billion by Inverness Medical Innovations.
 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.